# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

> **NCT02224664** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 50 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** PF-06649751
- **DRUG:** PF-06649751
- **DRUG:** PF-06649751
- **DRUG:** PF-06649751

## Key facts

- **NCT ID:** NCT02224664
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02224664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02224664, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02224664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*